Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31226Editorial articleПередовая статьяReview ArticleNonglycemic effects of dipeptidyl peptidase-4 inhibitorsНегликемические эффекты ингибиторов дипептидилпептидазы-4AmetovA SАметовА СKamyninaL LКамынинаЛ Лpetrology@yandex.ruГБОУ ДПО "Российская медицинская академия последипломного образования" Минздрава РФ, Москва15012013851VOL 85, NO1 ()ТОМ 85, №1 (2013)9810210042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31226

The review considers the major nonglycemic effects of dipeptidyl peptidase-4 inhibitors commonly used in diabetological practice, by using as an example sitagliptin, the first and most investigated representative of this class.

Аннотация. В обзоре рассмотрены основные негликемические эффекты широко используемых в диабетологической практике ингибиторов дипептидилпептидазы-4 на примере ситаглиптина - первого и наиболее изученного представителя этого класса.

type 2 diabetes mellitusdipeptidyl peptidase-4 inhibitorssitagliptinnonglycemic effectsсахарный диабет 2-го типаингибиторы дипептидилпептидазы-4ситаглиптиннегликемические эффектыKim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60 (4): 470-512.Stonehouse A.H., Darsow T., Maggs D.G. Incretin-based therapies. J Diabetes 2012; 4 (1): 55-67.Grieve D.J., Cassidy R.S., Green B.D. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 2009; 157 (8): 1340-1351.Arechavaleta R., Seck T., Chen Y. et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011; 13 (2): 160-168Hong E.S., Khang A.R., Yoon J.W. et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab 2012; 14 (9): 795-802.Yanai H., Adachi H., Hamasaki H. et al. Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis. J Clin Med Res 2012; 4 (4): 251-258.Öz Ö., Kıyıcı S., Ersoy C. et al. Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes. Diabetes Res Clin Pract 2011; 94 (2): 212-216.Monami M., Vitale V., Ambrosio M.L. et al. Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials. Adv Ther 2012; 29 (9): 736-746.Derosa G., Ragonesi P.D., Arrigo E.F. Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. Fund Clin Pharm 2012; doi:1 0.1111/fcp.12001. [Accepted 03-Sep-2012]Liu L., Liu J., Wong W.T. et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like Peptide 1-dependent mechanism. Hypertension 2012; 60 (3): 833-841.Marney A., Kunchakarra S., Byrne L., Brown N.J. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010; 56 (4): 728-733.Green J.B. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety. Postgrad Med 2012; 124 (4): 54-61.Ye Y., Perez-Polo J.R., Aguilar D., Birnbaum Y. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol 2011; 106 (6): 925-952.Ye Y., Keyes K.T., Zhang C. et al. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010; 298 (5): H1454-1465.Post S., van den Broek A.J., Rensing B. et al. Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction: Insights from the REPERATOR study. J Mol Cell Cardiol 2012 Sep 9. pii: S0022-2828(12)00331-8.Theiss H.D., Brenner C., Engelmann M.G. et al. Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) - rationale, design and first interim analysis. Int J Cardiol 2010; 145 (2): 282-284.Gomez N., Touihri K., Matheeussen V. et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail 2012; 14 (1): 14-21.Makdissi A., Ghanim H., Vora M. et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 2012; 97 (9): 3333-3341.Ferreira L., Teixeira-de-Lemos E., Pinto F. et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010; Article ID 592760, 11 pages doi:10.1155/2010/592760.Mega C., de Lemos E.T., Vala H. et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011; 2011: 162092.Gupta A.K., Verma A.K., Kailashiya J. et al. Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers. Platelets 2012; 23 (8): 565-570.Maiztegui B., Borelli M.I., Madrid V.G. et al. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased Β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond) 2011; 120 (2): 73-80.Gupta N.A., Mells J., Dunham R.M. et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51 (5): 1584-1592.Iwasaki T., Yoneda M., Inamori M. et al. Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 2011; 58 (112): 2103-2105.Iwasaki T., Tomeno W., Yoneda M. et al. Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. Hepatogastroenterology 2012; 59 (117): 1522-1555.Garg R., Chen W., Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy clAIM: analysis. Diabetes Care 2010; 33 (11): 2349-2354.Engel S.S., Williams-Herman D.E., Golm G.T. et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010; 64 (7): 984-990.Chan J.C., Scott R., Ferreira A.J.C. et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008; 10 (7): 545-555.Pendergrass M., Fenton C., Haffner S.M., Chen W. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective clAIM: analysis. Diabetes Obes Metab 2012; 14 (7): 596-600.Penfornis A., Bourdel-Marchasson I., Quere S., Dejager S. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study. Diabetes Metab. 2012 Sep 17. pii: S1262-3636(12)00121-8.Salti I., Bénard E., Detournay B. et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004; 27 (10): 2306-2311.Al Sifri S., Basiounny A., Echtay A. et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract 2011; 65 (11): 1132-1140.